Overall, our findings suggest that HPV mRNA-LNP vaccination in combination with immune checkpoint blockade can sustain the expansion and effector function of HPV-specific CD8+ T cells, thereby promoting tumor regression. The gene discussed is CD8A; the disease is neoplasm.